Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer

American Journal of Clinical Pathology

Volumn 140, Issue 4, 2013, Pages 468-474

  Nguyen, Thuy L ^a   Grizzle, William E ^a   Zhang, Kui ^b   Hameed, Omar ^a   Siegal, Gene P ^a   Wei, Shi ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; Prognosis; Subtype; Syndecan 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SYNDECAN 1;

ADULT; ADVANCED CANCER; AGED; BONE METASTASIS; BREAST CARCINOMA; CANCER CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SIZE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM METASTASIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS;

BREAST CANCER; PROGNOSIS; SUBTYPE; SYNDECAN-1;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; SYNDECAN-1; TENNESSEE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884958346     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPZ1D8CALHDXCJ     Document Type: Conference Paper

References (48)

1. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997;327:1-16. (Pubitemid 27455453)
2. Elenius K, Jalkanen M. Function of the syndecans: a family of cell surface proteoglycans. J Cell Science. 1994;107:2975-2982. (Pubitemid 24365201)
3. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med. 1996;28:63-67. (Pubitemid 26056048)
4. Solursh M, Reiter RS, Jensen KL, et al. Transient expression of a cell surface heparan sulfate proteoglycan (syndecan) during limb development. Dev Biol. 1990;140(1):83-92.
5. Day RM, Hao X, Ilyas M, et al. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch. 1999;434:121-125. (Pubitemid 29184989)
6. Gokden N, Greene GF, Bayer-Garner IB, et al. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol. 2006;14:173-177. (Pubitemid 43941180)
7. Inki P, Joensuu H, Grenman R, et al. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer. 1994;70:319-323. (Pubitemid 24247157)
8. Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003;55:20-29. (Pubitemid 36397741)
9. Nunez AL, Siegal GP, Reddy VV, et al. CD138 (syndecan-1) expression in bone-forming tumors. Am J Clin Pathol. 2012;137:423-428.
10. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001;12:89-98.
11. Sanderson RD, Yang Y, Kelly T, et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005;96:897-905. (Pubitemid 41688716)
12. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004;64:612-621. (Pubitemid 38120901)
13. Hirabayashi K, Numa F, Suminami Y, et al. Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumour Biol. 1998;19:454-463. (Pubitemid 28539327)
14. Lü ZL, Zhang WM, Xiao G, et al. Study of expression of CD138 and heparinase in hepatocellular carcinoma by tissue microarray [Chinese]. Zhonghua Bing Li Xue Za Zhi. 2006;35:82-86. (Pubitemid 43287118)
15. Nackaerts K, Verbeken E, Deneffe G, et al. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer. 1997;74:335-345. (Pubitemid 27321806)
16. Inki P, Stenback F, Grenman S, et al. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix. J Pathol. 1994;172:349-355. (Pubitemid 24168652)
17. Inki P, Larjava H, Haapasalmi K, et al. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Cell Biol. 1994;63:43-51. (Pubitemid 2039154)
18. Anttonen A, Kajanti M, Heikkila P, et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 1999;79:558-564. (Pubitemid 29046236)
19. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res. 2001;92:1062-1073. (Pubitemid 33041175)
20. Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88:12-20.
21. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000;25:329-332. (Pubitemid 30437323)
22. Beauvais DM, Rapraeger AC. Syndecan-1-mediated cell spreading requires signaling by ?v3 integrins in human breast carcinoma cells. Exp Cell Res. 2003;286:219-232. (Pubitemid 36566435)
23. Matsuda K, Maruyama H, Guo F, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001;61:5562-5569. (Pubitemid 32694943)
24. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98:474-483. (Pubitemid 36885986)
25. Lendorf ME, Manon-Jensen T, Kronqvist P, et al. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem. 2011;59:615-629.
26. Leivonen M, Lundin J, Nordling S, et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology. 2004;67:11-18. (Pubitemid 39370345)
27. Baba F, Swartz K, van Buren R, et al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptornegative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat. 2006;98:91-98. (Pubitemid 44050783)
28. Stanley MJ, Stanley MW, Sanderson RD, et al. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol. 1999;112:377-383. (Pubitemid 30214778)
29. Loussouarn D, Campion L, Sagan C, et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 2008;98:1993-1998. (Pubitemid 351821565)
30. Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009;17:393-402.
31. Wei S, Li Y, Siegal GP, et al. Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Ann Diagn Pathol. 2011;15:79-83.
32. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. (Pubitemid 43854964)
33. Blackhall FH, Merry CL, Davies EJ, et al. Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001;85:1094-1098. (Pubitemid 33052304)
34. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
35. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. (Pubitemid 32878711)
36. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423. (Pubitemid 36842560)
37. Gotte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 2006;26:621-627. (Pubitemid 43206026)
38. Mitselou A, Skoufi U, Tsimogiannis KE, et al. Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma. Anticancer Res. 2012;32:3977-3985.
39. Lamorte S, Ferrero S, Aschero S, et al. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia. 2012;26:1081-1090.
40. Khotskaya YB, Dai Y, Ritchie JP, et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem. 2009;284:26085-26095.
41. Oh JH, Lee HS, Park SH, et al. Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model. Int J Gynecol Cancer. 2010;20:751-756.
42. Beauvais DM, Ell BJ, McWhorter AR, et al. Syndecan-1 regulates v3 and v5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med. 2009;206:691-705.
43. Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest. 2009;119:1429-1437.
44. Hannafon BN, Sebastiani P, de las Morenas A, et al. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011;13:R24.
45. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682-688. (Pubitemid 47552092)
46. Gee HE, Camps C, Buffa FM, et al. MicroRNA-10b and breast cancer metastasis. Nature. 2008;455:E8-E9.
47. Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30:397-407.
48. Rousseau C, Ruellan AL, Bernardeau K, et al. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy: a preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Research. 2011;1:20.